STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [ARS] GALECTIN THERAPEUTICS INC SEC Filing

[ARS] GALECTIN THERAPEUTICS INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - GALECTIN THERAPEUTICS INC

ARS Filing - GALECTIN THERAPEUTICS INC

This filing is available as a PDF document.

Filing Type: ARS

Company: GALECTIN THERAPEUTICS INC (GALT)

Acceptance Date: 2025-10-22T08:01:40.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Galectin Therapeutics Inc

NASDAQ:GALT

View GALT Stock Overview →

GALT Rankings

#4580 Ranked by Market Cap
N/A Ranked by Dividends

GALT Latest News

Mar 17, 2026
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Feb 26, 2026
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Dec 19, 2025
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Nov 14, 2025
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Nov 10, 2025
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting

GALT Latest SEC Filings

Mar 17, 2026
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity
Mar 17, 2026
[Form 3] GALECTIN THERAPEUTICS INC Initial Statement of Beneficial Ownership
Mar 17, 2026
[8-K] GALECTIN THERAPEUTICS INC Reports Material Event
Feb 9, 2026
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity
Jan 22, 2026
[Form 4/A] GALECTIN THERAPEUTICS INC Amended Insider Trading Activity

GALT Stock Data

180.52M
45.21M
Biotechnology
Pharmaceutical Preparations
Link
United States
NORCROSS